Contact this trialFirst, we need to learn more about you.
Sodium Glucose Co-Transporter-2 Inhibitor
SGLT2 Inhibitor + GLP-1 Agonist for Kidney Transplant Recipients
Recruiting1 awardPhase 2
Toronto, Ontario
This trial is testing two diabetes medications, dapagliflozin and semaglutide, alone and together, in kidney transplant patients. The goal is to see if these drugs can safely protect their kidneys and hearts by lowering blood sugar and blood pressure. Dapagliflozin has shown benefits in reducing cardiovascular and kidney issues in chronic kidney disease patients, while semaglutide has demonstrated kidney-protective effects in type 2 diabetes patients.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service